Immunovant Inc. (IMVT) Statistics & Valuation Metrics - Stocknear

Immunovant Inc.

NASDAQ: IMVT · Real-Time Price · USD
16.90
0.17 (1.02%)
At close: Oct 03, 2025, 3:59 PM
17.00
0.59%
After-hours: Oct 03, 2025, 07:50 PM EDT

Immunovant Statistics

Share Statistics

Immunovant has 174.32M shares outstanding. The number of shares has increased by 18.76% in one year.

174.32M
18.76%
1.99%
56.32%
66.98M
200
0.01%

Short Selling Information

The latest short interest is 16.15M, so 9.26% of the outstanding shares have been sold short.

16.15M
9.26%
27.01%
7.72

Valuation Ratios

The PE ratio is -6.26 and the forward PE ratio is -5.83. Immunovant's PEG ratio is -0.14.

-6.26
-5.83
0
280.8
3.66
-6.88
-0.14
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Immunovant.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 11.16, with a Debt / Equity ratio of 0.

11.16
11.16
0
n/a
n/a
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.14M
362
0
n/a

Taxes

891K
-0.22%

Stock Price Statistics

The stock price has increased by -44.61% in the last 52 weeks. The beta is 0.48, so Immunovant's price volatility has been higher than the market average.

0.48
-44.61%
15.75
17.81
59.64
1,491,552

Income Statement

n/a
-377K
-438.15M
-413.84M
-412.57M
-412.95M
-2.73
Full Income Statement

Balance Sheet

The company has 713.97M in cash and 98K in debt, giving a net cash position of 713.87M.

713.97M
98K
713.87M
-1.24B
661.44M
598.86M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -375.87M and capital expenditures -759K, giving a free cash flow of -376.63M.

-375.87M
-759K
-376.63M
-2.48
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

IMVT does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for IMVT is $35, which is 107.1% higher than the current price. The consensus rating is "Buy".

$35
107.1%
Buy
9
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

27
1